Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Section 1 - General aspects

References

1. MayeuxT, MarderK, CoteLJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol 1995; 142: 820–7.
2. ZhangZX, RomanGC.Worldwide occurrence of Parkinson's disease: An updated review. Neuroepidemiology 1993; 12: 195–208.
3. De RijkMC, LaunerLJ, BergerK, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54 (Suppl 5): S21–3.
4. GasserT.Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009; 11: e22.
5. MarderK, LevyG, LouisED, et al. Familial aggregation of early- and late-onset Parkinson's disease. Ann Neurol 2003; 54: 507–13.
6. Di MonteDA.The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2003; 2: 531–8.
7. TannerCM.Advances in environmental epidemiology. Mov Disord 2010; 25 (Suppl 1): S58–62.
8. VendaLL, CraggSJ, BuchmanVL, Wade-MartinsR.α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 2010; 33: 559–68.
9. YavichL, TanilaH, VepsäläinenS, JäkäläP.Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 2004; 24: 11165–70.
10. NemaniVM, LuW, BergeV, et al. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2004; 65: 66–79.
11. MatsudaN, TanakaK.Does impairment of ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease? J Alzheimers Dis 2010; 19: 1–9.
12. SchapiraAH, JennerP.Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011; 26: 1049–55.
13. LuoGR, LeWD.Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases. Curr Pharm Biotechnol 2010; 11: 180–7.
14. BarnumCJ, TanseyMG.Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 2010; 184: 113–32.
15. GasserT, HardyJ, MizunoY.Milestones in PD genetics. Mov Disord 2011; 26: 1042–8.
16. ShultsCW.Lewy bodies. Proc Natl Acad Sci U S A 2006; 103: 1661–8.
17. FearnleyJM, LeesAJ.Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283–301.
18. BraakH, GhebremedhinE, RübU, BratzkeH, Del TrediciK.Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121–34.
19. ChaudhuriKR, OdinP.The challenge of non-motor symptoms in Parkinson's disease. Prog Brain Res 2010; 184: 325–41.
20. BraakH, Del TrediciK, RübU, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197–211.
21. SavicaR, RoccaWA, AhlskogJE.When does Parkinson disease start? Arch Neurol 2010; 67: 798–801.
22. ChaudhuriKR, Martinez-MartinP, SchapiraAH, et al. An international multicentre pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916–23.
23. GoetzCG, TilleyBC, ShaftmanSR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129–70.
24. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG.The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
25. ChaudhuriKR, HealyDG, SchapiraAH.Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235–45.
26. AbbottRD, RossGW, PetrovitchH, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007; 22: 1581–6.
27. DicksonDW, FujishiroH, OrrC, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009; 15: S1–5.
28. FujishiroH, FrigerioR, BurnettM, et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 2008; 23: 1085–92.
29. WingeK, FowlerCJ.Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21: 737–45.
30. Martinez-MartinP, Rodriguez-BlazquezC, KurtisMM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399–406.
31. BrooksDJ.Imaging dopamine transporters in Parkinson's disease. Biomark Med 2010; 4: 651–60.
32. ReichmannH.Clinical criteria for the diagnosis of Parkinson's disease. Neurodegener Dis 2010; 7: 284–90.
33. SatoK, HatanoT, YamashiroK, et al. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord 2006; 21: 1384–95.
34. ElbazA, BowerJH, PetersonBJ, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 2003; 60: 91–6.
35. ForsaaEB, LarsenJP, Wentzel-LarsenT, AlvesG.What predicts mortality in Parkinson disease? A prospective population-based long term study. Neurology 2010; 75: 1270–6.
36. GoodwinVA, RichardsSH, TaylorRS, TaylorAH, CampbellJL.The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2008; 23: 631–40.
37. XuQ, ParkY, HuangX, et al. Physical activities and future risk of Parkinson disease. Neurology 2010; 75: 341–8.
38. DiazNL, WatersCH.Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Rev Neurother 2009; 9: 1781–9.
39. ClarkeCE, WorthP, GrossetD, StewartD.Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 728–41.
40. StoweR, IvesN, ClarkeCE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 2011; 26: 587–98.
41. FoxSH, KatzenschlagerR, LimSY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's Disease. Mov Disord 2011; 26 (Suppl 3): S2–41.
42. OlanowCW, RascolO, HauserR, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.
43. FollettKA, WeaverFM, SternM, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362: 2077–91.
44. SchüpbachWM, ChastanN, WelterML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1640.
45. BronsteinJM, TagliatiM, AltermanRL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011; 68: 165–71.
46. WoodLD, NeumillerJJ, SetterSM, DobbinsEK.Clinical review of treatment options for select non-motor symptoms of Parkinson's disease. Am J Geriatr Pharmacother 2010; 8: 294–315.
47. MorleyJF, HurtigHI.Current understanding and management of Parkinson disease: five new things. Neurology 2010; 75: S9–14.
48. GagneJJ, PowerMC.Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74: 995–1002.

References

1. Rodrigues e SilvaAM, GeldsetzerF, HoldorffB, et al. Who was the man who discovered the “Lewy bodies”? Mov Disord 2010; 25: 1765–73.
2. LewyFH.Zur pathologischen Anatomie der Paralysis Agitans. Dtsch Z Nervenheilkd 1913; 50: 50–5.
3. Tretiakoff, C.Contribution a l’étude de l’anatomie pathologique du locus niger. University of Paris, 1919.
4. LewyFH.Die Lehre vom Tonus und der Bewegung: zugleich systematische Untersuchungen zur Klinik, Physiologie, Pathologie und Pathogenese der Paralysis Agitans. Berlin: Springer, 1923.
5. PearceJM.The Lewy body. J Neurol Neurosurg Psychiatry 2001; 71: 214.
6. LeesAJ, SelikhovaM, AndradeLA, DuyckaertsC.The black stuff and Konstantin Nikolaevich Tretiakoff. Mov Disord 2008; 23: 777–83.
7. GalvinJE, LeeVM, SchmidtML, et al. Pathobiology of the Lewy body. Adv Neurol 1999; 80: 313–24.
8. LeverenzJB, UmarI, WangQ, et al. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol 2007; 17: 139–45.
9. PolymeropoulosMH, LavedanC, LeroyE, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276: 2045–7.
10. SpillantiniMG, SchmidtML, LeeVM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40.
11. Chartier-HarlinMC, KachergusJ, RoumierC, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 2004; 364: 1167–9.
12. MurphyDD, RueterSM, TrojanowskiJQ, LeeVM.Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000; 20: 3214–20.
13. Schulz-SchaefferWJ.The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 2010; 120: 131–43.
14. SchneiderJA, BieniasJL, GilleyDW, et al. Improved detection of substantia nigra pathology in Alzheimer’s disease. J Histochem Cytochem 2002; 50: 99–106.
15. BraakH, Del TrediciK, BratzkeH, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 2002; 249 (Suppl 3): III/1–5.
16. AarslandD, PerryR, BrownA, LarsenJP, BallardC.Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 2005; 58: 773–6.
17. DicksonDW, UchikadoH, FujishiroH, TsuboiY.Evidence in favor of Braak staging of Parkinson’s disease. Mov Disord 2010; 25 (Suppl 1): S78–82.
18. LeverenzJB, HamiltonR, TsuangDW, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 2008; 18: 220–4.
19. ZaccaiJ, BrayneC, McKeithI, et al. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008; 70: 1042–8.
20. BurkeRE, DauerWT, VonsattelJP.A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 2008; 64: 485–91.
21. TekinS, CummingsJL.Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002; 53: 647–54.
22. ZgaljardicDJ, BorodJC, FoldiNS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson’s disease. J Clin Exp Neuropsychol 2006; 28: 1127–44.
23. RaoH, MamikonyanE, DetreJA, et al. Decreased ventral striatal activity with impulse control disorders in Parkinson’s disease. Mov Disord 2010; 25: 1660–9.
24. Chan-PalaV, AsanE.Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol 1989; 287: 373–92.
25. HardingAJ, BroeGA, HallidayGM.Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391–403.
26. CarlesimoGA, PirasF, AssognaF, et al. Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study. Neurology 2012; 78: 1939–45.
27. BraakH, RübU, Jansen SteurEN, Del TrediciK, de VosRA.Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64: 1404–10.
28. EmreM.Dementia associated with Parkinson’s disease. Lancet Neurol 2003; 2: 229–37.
29. AarslandD, AndersenK, LarsenJP, LolkA, Kragh-SørensenP.Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387–92.
30. AarslandD, BrønnickK, LarsenJP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121–6.
31. AarslandD, LarsenJP, KarlsenK, LimNG, TandbergE.Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866–74.
32. AarslandD, LarsenJP, TandbergE, LaakeK.Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938–42.
33. ButerTC, van den HoutA, MatthewsFE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017–22.
34. McKeithIG, DicksonDW, LoweJ, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–72.
35. HurtigHI, TrojanowskiJQ, GalvinJ, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000; 54: 1916–21.
36. ApaydinH, AhlskogJE, ParisiJE, BoeveBF, DicksonDW.Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: 102–12.
37. GalvinJE, PollackJ, MorrisJC.Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67: 1605–11.
38. IrwinDJ, WhiteMT, ToledoJB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587–98.
39. BlennowK, HampelH, WeinerM, ZetterbergH.Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131–44.
40. MontineTJ, ShiM, QuinnJF, et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010; 25: 2682–5.
41. ClintonLK, Blurton-JonesM, MyczekK, TrojanowskiJQ, LaFerlaFM.Synergistic interactions between Aβ, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281–9.
42. WhiteL, PetrovitchH, HardmanJ, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 2002; 977: 9–23.
43. SonnenJA, LarsonEB, CranePK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007; 62: 406–13.
44. JellingerKA, AttemsJ.Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008; 115: 427–36.
45. SchneiderJA, ArvanitakisZ, BangW, BennettDA.Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197–204.
46. ClaassenDO, JosephsKA, AhlskogJE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010; 75: 494–9.
47. FrisinaPG, HaroutunianV, LibowLS.The neuropathological basis for depression in Parkinson’s disease. Parkinsonism Relat Disord 2009; 15: 144–8.
48. RemyP, DoderM, LeesA, TurjanskiN, BrooksD.Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314–22.
49. KostićVS, AgostaF, PetrovićI, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 2010; 75: 857–63.
50. MaybergHS, StarksteinSE, SadzotB, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 1990; 28: 57–64.
51. RingHA, BenchCJ, TrimbleMR, et al. Depression in Parkinson’s disease: a positron emission study. Br J Psychiatry 1994; 165: 333–9.
52. MatsuiH, NishinakaK, OdaM, et al. Depression in Parkinson’s disease: diffusion tensor imaging study. J Neurol 2007; 254: 1170–3.
53. SeppiK, WeintraubD, CoelhoM, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011; 26 (Suppl 3): S42–80.
54. HardingAJ, StimsonE, HendersonJM, HallidayGM.Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain 2002; 125: 2431–45.
55. KimMJ, LoucksRA, PalmerAL, et al. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res 2011; 223: 403–10.
56. WeintraubD, KoesterJ, PotenzaMN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.
57. ReijndersJS, ScholtissenB, WeberWE, et al. Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 2010; 25: 2318–25.
58. DujardinK, SockeelP, DelliauxM, DestéeA, DefebvreL.Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 2009; 24: 2391–7.
59. PedersenKF, LarsenJP, AlvesG, AarslandD.Prevalence and clinical correlates of apathy in Parkinson’s disease: a community-based study. Parkinsonism Relat Disord 2009; 15: 295–9.
60. Le JeuneF, DrapierD, BourguignonA, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009; 73: 1746–51.
61. BruenPD, McGeownWJ, ShanksMF, VenneriA.Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain 2008; 131: 2455–63.
62. BohnenNI, KauferDI, IvancoLS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745–8.
63. RoddaJ, MorganS, WalkerZ.Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer’s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009; 21: 813–24.
64. GerlachM, DoubleK, ArzbergerT, et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003; 110: 1119–27.
65. GrantJE, BrewerJA, PotenzaMN.The neurobiology of substance and behavioral addictions. CNS Spectr 2006; 11: 924–30.
66. FénelonG, Alves, G.Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 2010; 289: 12–17.
67. GoldmanJG.New thoughts on thought disorders in Parkinson’s disease: review of current research strategies and challenges. Parkinsons Dis 2011; 2011: 675630.
68. WoltersE.PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl 2006; 71: 31–7.
69. McKeithI, Del SerT, SpanoP, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–6.
70. EmreM, AarslandD, AlbaneseA, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–18.
71. JanzenJ, van 't EntD, LemstraAW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. J Neurol 2012; 259: 147–54.
72. GoetzCG, PappertEJ, BlasucciLM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50: 515–17.
73. FénelonG, GoetzCG, KarenbergA.Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006; 66: 93–8.
74. BallangerB, StrafellaAP, van EimerenT, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416–21.
75. HuotP, JohnstonTH, DarrT, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010; 25: 1399–408.
76. Ibarretxe-BilbaoN, Ramirez-RuizB, JunqueC, et al. Differential progression of brain atrophy in Parkinson’s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 2010; 81: 650–7.
77. OkadaK, SuyamaN, OguroH, YamaguchiS, KobayashiS.Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. J Neurol 1999; 246: 365–8.
78. HolroydS, WootenGF.Preliminary fMRI evidence of visual system dysfunction in Parkinson’s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci 2006; 18: 402–4.
79. WilliamsDR, LeesAJ.Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605–10.
80. TsuangD, LarsonEB, BolenE, et al. Visual hallucinations in dementia: a prospective community-based study with autopsy. Am J Geriatr Psychiatry 2009; 17: 317–23.
81. DuggerBN, MurrayME, BoeveBF, et al. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathol Appl Neurobiol 2012; 38: 142–52.
82. WallaceDM, ShafazandS, CarvalhoDZ, et al. Sleep-related falling out of bed in Parkinson’s disease. J Clin Neurol 2012; 8: 51–7.
83. BoeveBF, SilberMH, SaperCB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007; 130: 2770–88.
84. Sixel-DöringF, TrautmannE, MollenhauerB, TrenkwalderC.Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology 2011; 77: 1048–54.
85. ThannickalTC, LaiYY, SiegelJM.Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 2007; 130: 1586–95.
86. SchenckC, MahowaldM.A polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Clev Clin J Med 1990; 57 (suppl): 10–24.
87. KunzD, BesF.Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999; 14: 507–11.
88. TakeuchiN, UchimuraN, HashizumeY, et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001; 55: 267–9.

References

1. PolymeropoulosMH, LavedanC, LeroyE, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276: 2045–7.
2. BekrisLM, MataIF, ZabetianCP.The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23: 228–42.
3. KleinC, Lohmann-HedrichK.Impact of recent genetic findings in Parkinson’s disease. Curr Opin Neurol 2007; 20: 453–64.
4. FoltynieT, SawcerS, BrayneC, BarkerRA.The genetic basis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73: 363–70.
5. International Parkinson’s Disease Genomics Consortium (IPDGC), Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson’s disease. PLoS Genet 2011; 7: e1002142.
6. International Parkinson Disease Genomics Consortium, NallsMA, PlagnolV, et al. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377: 641–9.
7. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG.The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
8. AarslandD, AndersenK, LarsenJP, LolkA, Kragh-SørensenP.Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387–92.
9. KastenM, KertelgeL, BrüggemannN, et al. Nonmotor symptoms in genetic Parkinson disease. Arch Neurol 2010; 67: 670–6.
10. SteinlechnerS, StahlbergJ, VolkelB, et al. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J Neurol Neurosurg Psychiatry 2007; 78: 532–5.
11. AarslandD, ZaccaiJ, BrayneC.A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005; 20: 1255–63.
12. FarrerM, KachergusJ, FornoL, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55: 174–9.
13. Chartier-HarlinMC, KachergusJ, RoumierC, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 2004; 364: 1167–9.
14. EmreM, AarslandD, BrownR, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689–707.
15. FoltynieT, BrayneCE, RobbinsTW, BarkerRA.The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 2004; 127: 550–60.
16. Williams-GrayCH, EvansJR, GorisA, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958–69.
17. Williams-GrayCH, MasonSL, EvansJR, FoltynieT, BarkerRA.The CamPaIGN study of incident Parkinson’s disease: natural history over the first 10 years (abstract). Mov Disord 2012; 27: S522–3.
18. OwenAM.Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist 2004; 10: 525–37.
19. AarslandD, PerryR, BrownA, LarsenJP, BallardC.Neuropathology of dementia in Parkinson’s disease: A prospective, community-based study. Ann Neurol 2005; 58: 773–6.
20. ComptaY, ParkkinenL, O’SullivanSS, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 2011; 134: 1493–505.
21. BohnenNI, KauferDI, IvancoLS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745–8.
22. EmreM, AarslandD, AlbaneseA, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–18.
23. HilkerR, ThomasAV, KleinJC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716–22.
24. BohnenNI, KauferDI, HendricksonR, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006; 253: 242–7.
25. VelayatiA, YuWH, SidranskyE.The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 2010; 10: 190–8.
26. MoronJA, BrockingtonA, WiseRA, RochaBA, HopeBT.Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22: 389–95.
27. MazeiMS, PlutoCP, KirkbrideB, PehekEA.Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res 2002; 936: 58–67.
28. LewisDA, MelchitzkyDS, SesackSR, et al. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol 2001; 432: 119–36.
29. KaroumF, ChrapustaSJ, EganMF.3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994; 63: 972–9.
30. GogosJA, MorganM, LuineV, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 1998; 95: 9991–6.
31. ChenJ, LipskaBK, HalimN, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807–21.
32. BarnettJH, JonesPB, RobbinsTW, MullerU.Effects of the catechol-O-methyltransferase Val(158)Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry 2007; 12: 502–9.
33. BlasiG, MattayVS, BertolinoA, et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci 2005; 25: 5038–45.
34. EganMF, GoldbergTE, KolachanaBS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 6917–22.
35. FoltynieT, GoldbergTE, LewisSG, et al. Planning ability in Parkinson’s disease is influenced by the COMT val158met polymorphism. Mov Disord 2004; 19: 885–91.
36. HooglandJ, de BieRM, Williams-GrayCH, et al. Catechol-O-methyltransferase val158met and cognitive function in Parkinson’s disease. Mov Disord 2010; 25: 2550–4.
37. Williams-GrayCH, HampshireA, BarkerRA, OwenAM.Attentional control in Parkinson’s disease is dependent on COMT val 158 met genotype. Brain 2008; 131: 397–408.
38. Williams-GrayCH, HampshireA, RobbinsTW, OwenAM, BarkerRA.Catechol O-methyltransferase val158met genotype influences frontoparietal activity during planning in patients with Parkinson’s disease. J Neurosci 2007; 27: 4832–8.
39. KaasinenV, NurmiE, BruckA, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson’s disease: sex differences in the prefrontal cortex. Brain 2001; 124: 1125–30.
40. RakshiJS, UemaT, ItoK, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease A 3D [(18)F]dopa-PET study. Brain 1999; 122 (Pt 9): 1637–50.
41. Goldman-RakicPS, MulyEC, WilliamsGV.D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000; 31: 295–301.
42. BrooksDJ, PicciniP.Imaging in Parkinson’s disease: the role of monoamines in behavior. Biol Psychiatry 2006; 59: 908–18.
43. PinsonneaultJK, PappAC, SadeeW.Allelic mRNA expression of X-linked monoamine oxidase A (MAOA) in human brain: dissection of epigenetic and genetic factors. Hum Mol Genet 2006; 15: 2636–49.
44. Williams-GrayC, GorisA, FoltynieT, et al. No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson’s disease. J Neurol 2009; 256: 132–3.
45. GalpernWR, LangAE.Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006; 59: 449–58.
46. GorisA, Williams-GrayCH, ClarkGR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol 2007; 62: 145–53.
47. IshizawaT, MattilaP, DaviesP, WangD, DicksonDW.Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003; 62: 389–97.
48. WaxmanEA, GiassonBI.Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 2011; 31: 7604–18.
49. HaggertyT, CredleJ, RodriguezO, et al. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson’s disease. Eur J Neurosci 2011; 33: 1598–610.
50. StefanssonH, HelgasonA, ThorleifssonG, et al. A common inversion under selection in Europeans. Nat Genet 2005; 37: 129–37.
51. Seto-SalviaN, ClarimonJ, PagonabarragaJ, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011; 68: 359–64.
52. Colom-CadenaM, GelpiE, MartiMJ, et al. MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies. Neurobiol Aging 2013; 34: 936–42.
53. WiderC, RossOA, NishiokaK, et al. An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer’s and Lewy body pathology. J Neurol Neurosurg Psychiatry 2012; 83: 424–9.
54. TobinJE, LatourelleJC, LewMF, et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 2008; 71: 28–34.
55. MyersAJ, PittmanAM, ZhaoAS, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007; 25: 561–70.
56. KwokJB, TeberET, LoyC, et al. Tau haplotypes regulate transcription and are associated with Parkinson’s disease. Ann Neurol 2004; 55: 329–34.
57. RademakersR, MelquistS, CrutsM, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005; 14: 3281–92.
58. CaffreyTM, JoachimC, ParacchiniS, EsiriMM, Wade-MartinsR.Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet 2006; 15: 3529–37.
59. FarrerLA, CupplesLA, HainesJL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349–56.
60. GallardoG, SchluterOM, SudhofTC.A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Aβ peptides. Nat Neurosci 2008; 11: 301–8.
61. Williams-GrayCH, GorisA, SaikiM, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J Neurol 2009; 256: 493–8.
62. KurzMW, DekomienG, NilsenOB, et al. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr Psychiatry Neurol 2009; 22: 166–70.
63. MorleyJF, XieSX, HurtigHI, et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov Disord 2012; 27: 512–18.
64. BallardCG.Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64–70.
65. PerryEK, PerryRH, BlessedG, TomlinsonBE.Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273–7.
66. PerryE, McKeithI, BallardC.Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003; 60: 1852–3.
67. BartelsCF, JensenFS, LockridgeO, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992; 50: 1086–103.
68. HolmesC, BallardC, LehmannD, et al. Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005; 76: 640–3.
69. LaneR, HeY, MorrisC, et al. BuChE-K and APOE ε4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009; 24: 392–400.
70. CapabloJL, Saenz de CabezonA, FraileJ, et al. Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J Neurol Neurosurg Psychiatry 2008; 79: 219–22.
71. WongK, SidranskyE, VermaA, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004; 82: 192–207.
72. WestbroekW, GustafsonAM, SidranskyE.Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 2011; 17: 485–93.
73. Goker-AlpanO, StubblefieldBK, GiassonBI, SidranskyE.Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010; 120: 641–9.
74. Seto-SalviaN, PagonabarragaJ, HouldenH, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson’s disease course. Mov Disord 2012; 27: 393–9.
75. NeumannJ, BrasJ, DeasE, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009; 132: 1783–94.
76. AlcalayRN, CaccappoloE, Mejia-SantanaH, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78: 1434–40.
77. SidranskyE, NallsMA, AaslyJO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009; 361: 1651–61.
78. Williams-GrayCH, FoltynieT, LewisSJ, BarkerRA.Cognitive deficits and psychosis in Parkinson’s disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006; 20: 477–505.
79. MakoffAJ, GrahamJM, ArranzMJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics 2000; 10: 43–8.
80. GoetzCG, BurkePF, LeurgansS, et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 2001; 58: 209–13.
81. WangJ, ZhaoC, ChenB, LiuZL.Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson’s disease. Neurosci Lett 2004; 355: 193–6.
82. FujiiC, HaradaS, OhkoshiN, et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson’s disease. Clin Genet 1999; 56: 394–9.
83. WangJ, SiYM, LiuZL, YuL.Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson’s disease. Pharmacogenetics 2003; 13: 365–9.
84. GoldmanJG, MarrD, ZhouL, et al. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson’s disease hallucinations. Mov Disord 2011; 26: 1781–2.
85. AarslandD, LarsenJP, CumminsJL, LaakeK.Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595–601.
86. BurnD, EmreM, McKeithI, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21: 1899–907.
87. PapapetropoulosS, FarrerMJ, StoneJT, et al. Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 2007; 414: 141–4.
88. FactorSA, SteenlandNK, HigginsDS, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Disord 2011; 26: 2190–5.
89. BurnDJ.Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov Disord 2002; 17: 445–54.
90. LeschKP, BengelD, HeilsA, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–31.
91. MenzaMA, PalermoB, DiPaolaR, SageJI, RickettsMH.Depression and anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999; 12: 49–52.
92. MossnerR, HennebergA, SchmittA, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson’s disease. Mol Psychiatry 2001; 6: 350–2.
93. BurnDJ, TiangyouW, AllcockLM, DavisonJ, ChinneryPF.Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson’s disease. Parkinsonism Relat Disord 2006; 12: 139–41.
94. ZhangJL, YangJF, ChanP.No association between polymorphism of serotonin transporter gene and depression in Parkinson’s disease in Chinese. Neurosci Lett 2009; 455: 155–8.
95. WeintraubD, KoesterJ, PotenzaMN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.
96. LeeJY, LeeEK, ParkSS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord 2009; 24: 1803–10.
97. EiseneggerC, KnochD, EbsteinRP, et al. Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. Biol Psychiatry 2010; 67: 702–6.
98. EvansJR, MasonSL, Williams-GrayCH, et al. The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011; 82: 1112–18.

References

1. McKeithIG, DicksonDW, LoweJ, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–72.
2. EmreM, AarslandD, BrownR, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689–707.
3. AarslandD, BrønnickK, Williams-GrayC, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062–9.
4. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG.The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
5. AarslandD, AndersenK, LarsenJP, LolkA, Kragh-SørensenP.Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387–92.
6. PletnikovaO, WestN, LeeMK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26: 1183–92.
7. JellingerKA, AttemsJ.Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?Acta Neuropathol 2006; 112: 253–60.
8. AarslandD, BallardCG, HallidayG.Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity?J Geriatr Psychiatry Neurol 2004; 17: 137–45.
9. FujishiroH, IsekiE, HigashiS, et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 2010; 486: 19–23.
10. HurtigHI, TrojanowskiJQ, GalvinJ, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000; 54: 1916–21.
11. AarslandD, PerryR, BrownA, LarsenJP, BallardC.Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 2005; 58: 773–6.
12. TsuboiY, DicksonDW.Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different?Parkinsonism Relat Disord 2005; 11 (Suppl 1): S47–51.
13. PiggottMA, BallardCG, DickinsonHO.Thalamic D2 receptors in dementia with Lewy bodies, Parkinson’s disease, and Parkinson’s disease dementia. Int J Neuropsychopharmacol 2007; 10: 231–44.
14. BallardC, ZiabrevaI, PerryR, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67: 1931–4.
15. BraakH, Del TrediciK, RübU, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211.
16. SchneiderJA, ArvanitakisZ, BangW, BennettDA.Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197–204.
17. JellingerKA, AttemsJ.Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?Acta Neuropathol 2006; 112: 253–60.
18. BiblM, MollenhauerB, EsselmannH, et al. CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 2006; 129: 1177–87.
19. AertsMB, EsselinkRA, AbdoWF, BloemBR, VerbeekMM.CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012; 33: 430.e1–3.
20. MollenhauerB, LocascioJJ, Schulz-SchaefferW, et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10: 230–40.
21. KleinJC, EggersC, KalbeE, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885–92.
22. GalvinJE, PollackJ, MorrisJC.Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67: 1605–11.
23. BurnDJ, RowanEN, MinettT, et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003; 18: 884–9.
24. BurnDJ, RowanEN, AllanLM, et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585–9.
25. NoeE, MarderK, BellKL, et al. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 2004; 19: 60–7.
26. BallardCG, AarslandD, McKeithI, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59: 1714–20.
27. VaraneseS, PerfettiB, MonacoD, et al. Fluctuating cognition and different cognitive and behavioural profiles in Parkinson’s disease with dementia: comparison of dementia with Lewy bodies and Alzheimer’s disease. J Neurol 2010; 257: 1004–11.
28. AarslandD, BallardC, LarsenJP, McKeithI.A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 2001; 16: 528–36.
29. MosimannUP, RowanEN, PartingtonCE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153–60.
30. KuritaA, MurakamiM, TakagiS, MatsushimaM, SuzukiM.Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord 2010; 25: 167–71.
31. MosimannUP, MatherG, WesnesKA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004; 63: 2091–6.
32. JanvinCC, LarsenJP, SalmonDP, et al. Cognitive profiles of individual patients with Parkinson’s disease and dementia: comparison with dementia with Lewy bodies and Alzheimer’s disease. Mov Disord 2006; 21: 337–42.
33. HorimotoY, MatsumotoM, NakazawaH, et al. Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson’s disease with dementia. J Neurol Sci 2003; 216: 105–8.
34. MondonK, GochardA, MarquéA, et al. Visual recognition memory differentiates dementia with Lewy bodies and Parkinson’s disease dementia. J Neurol Neurosurg Psychiatry 2007; 78: 738–41.
35. FiloteoJV, SalmonDP, SchiehserDM, et al. Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson’s disease with dementia. J Clin Exp Neuropsychol 2009; 31: 823–34.
36. BoddyF, RowanEN, LettD, et al. Subjectively reported sleep quality and excessive daytime somnolence in Parkinson’s disease with and without dementia, dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22: 529–35.
37. AllanLM, BallardCG, AllenJ, et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 2007; 78: 671–7.
38. SuzukiM, KuritaA, HashimotoM, et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson’s disease. J Neurol Sci 2006; 240: 15–19.
39. AnderssonM, HanssonO, MinthonL, BallardCG, LondosE.The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. Int J Geriatr Psychiatry 2008; 23: 192–8.
40. IdiaquezJ, BenarrochEE, RosalesH, MillaP, RíosL.Autonomic and cognitive dysfunction in Parkinson’s disease. Clin Auton Res 2007; 17: 93–8.
41. PeraltaC, Stampfer-KountchevM, KarnerE, et al. Orthostatic hypotension and attention in Parkinson’s disease with and without dementia. J Neural Transm 2007; 114: 585–8.
42. AarslandD, PerryR, LarsenJP, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry 2005; 66: 633–7.
43. PaleacuD, SchechtmanE, InzelbergR.Association between family history of dementia and hallucinations in Parkinson disease. Neurology 2005; 64: 1712–15.
44. Jasinska-MygaB, OpalaG, GoetzCG, et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 2007; 64: 261–5.
45. LambH, ChristieJ, SingletonAB, et al. Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer’s disease and in dementia with Lewy bodies. Distinctions between diseases. Neurology 1998; 50: 388–91.
46. Cahn-WeinerDA, WilliamsK, GraceJ, et al. Discrimination of dementia with Lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn Behav Neurol 2003; 16: 85–92.
47. BeyerMK, LarsenJP, AarslandD.Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 2007; 69: 747–54.
48. LeeJE, ParkB, SongSK, et al. A comparison of gray and white matter density in patients with Parkinson’s disease dementia and dementia with Lewy bodies using voxel-based morphometry. Mov Disord 2010; 25: 28–34.
49. Sanchez-CastanedaC, ReneR, Ramirez-RuizB, et al. Correlations between gray matter reductions and cognitive deficits in dementia with Lewy bodies and Parkinson’s disease with dementia. Mov Disord 2009; 24: 1740–6.
50. BurtonEJ, McKeithIG, BurnDJ, FirbankMJ, O'BrienJT.Progression of white matter hyperintensities in Alzheimer disease, dementia with Lewy bodies, and Parkinson disease dementia: a comparison with normal aging. Am J Geriatr Psychiatry 2006; 14: 842–9.
51. LeeJE, ParkHJ, ParkB, et al. A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson’s disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2010; 81: 320–6.
52. MaetzlerW, LiepeltI, ReimoldM, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34: 107–12.
53. EdisonP, RoweCC, RinneJO, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331–8.
54. O’BrienJT, CollobyS, FenwickJ, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61: 919–25.
55. FirbankMJ, BurnDJ, McKeithIG, O'BrienJT.Longitudinal study of cerebral blood flow SPECT in Parkinson’s disease with dementia, and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20: 776–82.
56. YongSW, YoonJK, AnYS, LeePH.A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol 2007; 14: 1357–62.
57. BonanniL, ThomasA, TiraboschiP, et al. EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain 2008; 131: 690–705.
58. PerriolMP, DujardinK, DerambureP, et al. Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson’s disease dementia and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005; 76: 106–8.
59. MitoY, YoshidaK, YabeI, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson’s disease with and without dementia, and Alzheimer’s disease. Clin Neurol Neurosurg 2005; 107: 396–403.
60. CavannaAE, TrimbleMR.The precuneus: a review of its functional anatomy and behavioural correlates. Brain 2006; 129: 564–83.
61. WalterU, DresslerD, WoltersA, et al. Sonographic discrimination of dementia with Lewy bodies and Parkinson’s disease with dementia. J Neurol 2006; 253: 448–54.
62. McKeithI, Del SerT, SpanoP, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–6.
63. RowanE, McKeithIG, SaxbyBK, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson’s disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007; 23: 161–7.
64. EmreM, AarslandD, AlbaneseA, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–18.
65. MolloySA, RowanEN, O’BrienJT, et al. Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 1323–8.
66. MolloyS, McKeithIG, O'BrienJT, BurnDJ.The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005; 76: 1200–3.
67. BonelliSB, RansmayrG, SteffelbauerM, et al. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004; 63: 376–8.
68. AarslandD, BallardC, WalkerZ, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613–18.
69. EmreM, TsolakiM, BonuccelliU, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969–77.
70. LewisSJ, FoltynieT, BlackwellAD, et al. Heterogeneity of Parkinson’s disease in the early initial stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343–8.
71. SelikhovaM, WilliamsDR, KempsterPA, et al. A clinico-pathological study of subtypes in Parkinson’s disease. Brain 2009; 132: 2947–57.